Four investment groups with ties to the family that owns about 35% of Grifols SA confirmed they are in talks with Brookfield ...

IBL International has entered a strategic collaboration with healthcare company Grifols to develop biomarker panels for ...

Brookfield had filed a non-binding offer on Nov. 19 for Grifols that valued the developer of human plasma-based drugs at ...

Grifols and Brookfield said they aren't in takeover talks, after a media report indicated the investment company had resumed discussions with the Grifols family--which controls the Spanish ...

The Grifols family has held "very preliminary talks" through several investment firms over a potential takeover bid, according to a source close to the pharmaceutical company's reference shareholders.

Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols’ random access, single ...

Canadian investment fund Brookfield (NYSE:BAM) resumed talks on a potential takeover of Spanish pharmaceuticals company ...

Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare ...

The Board of Directors of the Grifols , S.A. has unanimously approved that its fully owned subsidiary Grifols Biotest Holdings GmbH, to make a public delisting purchase offer to t ...

In recent weeks, European markets have experienced significant turbulence, with the pan-European STOXX Europe 600 Index dropping 8.44%, marking its steepest decline in five years amid heightened ...

Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest AG: Delisting agreement and announced delisting tender offer eieich, March 31, 2025: Biotest AG (ISIN ...

Three investment firms linked to the Grifols family--Deria, Ponder Trade and Radellor--and a fourth called Scranton Enterprises confirmed Wednesday that the talks were initiated by Brookfield and were ...